How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

941 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Improving Human Papilloma Virus (HPV) Vaccine Uptake

Improving Human Papilloma Virus (HPV) Vaccine Uptake Improving Human Papilloma Virus (HPV) Vaccine Uptake A Rapid Review Region of Peel – Public Health Communicable Diseases Division October 2019 Please use the following citation when referencing this document: Region of Peel – Public Health. Improving Human Papilloma Virus (HPV) Vaccine Uptake: A rapid review. Mississauga, ON: Region of Peel – Public Health; 2019. Table of Contents KEY MESSAGES 1 EXECUTIVE SUMMARY 2 1 ISSUE 4 2 CONTEXT 5 3 (...) and meta-analysis of interventions to improve access and coverage of adolescent immunizations. J Adolesc Health. [Internet] Oct 2016 [cited July 29, 2019]; 59(4 Suppl): S40–S48. Available from: https://doi.org/10.1016/j.jadohealth.2016.07.005 13. Kang HS, De Gagne JC, Son YD & Chae SM. Completeness of human papilloma virus vaccination: a systematic review. J Pediatr Nurs. [Internet] Mar – Apr 2018 [cited July 29, 2019]; 39:7-14. Available from: https://doi.org/10.1016/j.pedn.2017.12.003 14. Niccolai LM

2020 Peel Health Library

2. Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope Full Text available with Trip Pro

Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope 29263867 2018 11 13 2059-0105 2 2017 NPJ vaccines NPJ Vaccines Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope. 6 10.1038/s41541-017-0004-x Head Michael G MG Faculty of Medicine, University of Southampton, Southampton, UK. 0000 0004 1936 9297 grid.5491.9 Wind-Mozley Magdalen M Independent researcher, Newbury, UK. Flegg Peter J PJ (...) Department of Medicine, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. grid.440172.4 eng Journal Article 2017 03 08 England NPJ Vaccines 101699863 2059-0105 2016 08 19 2016 10 10 2016 12 06 2017 12 22 6 0 2017 12 22 6 0 2017 12 22 6 1 epublish 29263867 10.1038/s41541-017-0004-x 4 PMC5627248 Vaccine. 2011 Oct 26;29(46):8279-84 21907257 Lancet Glob Health. 2016 Jul;4(7):e453-63 27340003 Lancet. 2015 Jun 27;385(9987):2571 26122153 J Adolesc Health. 2011 Nov;49(5):467-75 22018560 Vaccine

2017 NPJ Vaccines

3. The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus Full Text available with Trip Pro

The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus To determine if natural human papillomavirus (HPV) infection would induce an anamnestic response to quadrivalent (qHPV) vaccine in women with Systemic Lupus Erythematosus (SLE).Thirty four women (19-50 years) with mild to moderate and minimally active or inactive SLE received standard qHPV vaccine (...) . Neutralizing antibody titers to HPV 6, 11, 16 and18 were evaluated pre- and post- vaccine using HPV competitive Luminex Immunoassay. For each HPV type, logistic regressions were performed to explore the relationship between a positive titer at baseline with their final geometric mean titer and with the rise in titer. Fisher's Exact Test was used to assess the association of at least one positive HPV antibody test at baseline and history of abnormal pap.History of abnormal pap smear/cervical neoplasia

2018 Human vaccines & immunotherapeutics

4. Differences in human papilloma virus vaccination prevalence, testing, knowledge on vaccination, cancer awareness and sexual activities between male and female medical and non-medical students. (Abstract)

Differences in human papilloma virus vaccination prevalence, testing, knowledge on vaccination, cancer awareness and sexual activities between male and female medical and non-medical students. Although most European countries experienced a decrease in cervical cancer mortality, Ukraine, Latvia and Belarus have experienced an increase in mortality. There is no national vaccination programme against human papilloma virus (HPV) in Ukraine, and vaccination rates are low.To study the knowledge (...) of HPV-related cancers and vaccination amongst medical and non-medical students with a view to a better organization of educational interventions.Male and female students of the Bogomolets National Medical University and non-medical students of other universities from Kiev were asked to fill in an anonymous survey of HPV vaccination prevalence, testing, knowledge on vaccination, HPV-related cancer awareness and sexual activities.Medical students showed better knowledge, higher prevalence of HPV

2020 Journal of the European Academy of Dermatology and Venereology

5. Vaccine-preventable Infections and Immunization in Multiple Sclerosis

to Poser 11 or McDonald 12 criteria. Initially, the panel included only cases of MS diagnosed by a neurologist but later revised this requirement because many studies used computerized databases. Accepted control group criteria varied by question. For questions referencing the general population, studies with only neurologic disease control groups were excluded. 11 The panel included immunizations recommended by the US Centers for Disease Control and Prevention (CDC) 13 and vaccines suggested (...) with 10 untreated participants with MS and 4 HCs (combined control group). All participants in the treated and untreated groups had baseline immunity to at least one of the 3 viral strains; 9/42 possible participant-variant combinations in the control group and 8/51 in the daclizumab-treated group did not fulfill criteria for seroprotection on day 0 (denominators represent the combination of antibodies to all 3 virus strains tested in the group). After treatment with a trivalent influenza vaccine

2019 American Academy of Neurology

6. Correction to: Health system factors influencing uptake of human papilloma virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. Full Text available with Trip Pro

Correction to: Health system factors influencing uptake of human papilloma virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. In the original article [1] the first paragraph of the Background section was omitted due to a discrepancy between the metadata of the article and the PDF version.

2020 BMC Public Health

7. Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. Full Text available with Trip Pro

Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. Globally, cervical cancer is the fourth most common cancer in women with more than 85% of the burden in developing countries. In Uganda, cervical cancer has shown an increase of 1.8% per annum over the last 20 years. The availability of the Human Papillomavirus (HPV) vaccine presents an opportunity to prevent cervical cancer. Understanding how the health (...) system influences uptake of the vaccine is critical to improve it. This study aimed to assess how the health systems is influencing uptake of HPV vaccine so as to inform policy for vaccine implementation and uptake in Mbale district, Eastern Uganda.We conducted a cross sectional study of 407 respondents, selected from 56 villages. Six key informant interviews were conducted with District Health Officials involved in implementation of the HPV vaccine. Quantitative data was analyzed using Stata V.13

2020 BMC Public Health

8. Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)

information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Hospices Civils de Lyon: mucoviscidosis Human Papilloma Virus Vaccination Young girl Additional relevant MeSH terms: Layout table for MeSH terms Fibrosis Cystic Fibrosis Papilloma Pathologic Processes Pancreatic Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Neoplasms, Squamous Cell Neoplasms (...) Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2) Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

9. Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria Full Text available with Trip Pro

Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria HPV is one of the most common causes of sexually transmitted disease in both men and women worldwide. It is transmitted through vaginal, anal, and oral sex. This study provided information on the Human Papilloma Virus (HPV) vaccine awareness and vaccination history in relation to the level of antibodies to (HPV) in the population at risk in Nigeria. Patients attending (...) STI clinics at Lagos and Ibadan were recruited and informed consent was obtained from all the participants. Using semi structured questionnaire, vaccination history, demography and past experiences of the patients were obtained. Whole blood samples were obtained and the sera screened for specific antibodies to HPV using ELISA test kits for determination of IgG to HPV by DIA PRO Diagnostic Bioprobes Milano-Italy according to the manufacturer's instruction. Of the170 samples analysed 50 (29.4

2018 Archives of basic and applied medicine

10. How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda Full Text available with Trip Pro

How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda To date, research on priority-setting for new vaccines has not adequately explored the influence of the global, national and sub-national levels of decision-making or contextual issues such as political pressure and stakeholder influence and power. Using Kapiriri and Martin's conceptual framework, this paper evaluates priority setting for new (...) vaccines in Uganda at national and sub-national levels, and considers how global priorities can influence country priorities. This study focuses on 2 specific vaccines, the human papilloma virus (HPV) vaccine and the pneumococcal conjugate vaccine (PCV).This was a qualitative study that involved reviewing relevant Ugandan policy documents and media reports, as well as 54 key informant interviews at the global level and national and sub-national levels in Uganda. Kapiriri and Martin's conceptual

2017 International journal of health policy and management

11. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

of healthcare and social support systems, national vaccination programmes and professional society organisations with an interest in HPV and/or immunisation programmes. Guidance on HPV vaccination in EU countries: focus on boys, PLHIV and 9-valent HPV vaccine introduction SCIENTIFIC ADVICE 4 2. Background Human papilloma virus is one of the most widespread and common sexually transmitted infections worldwide and is acquired soon after the start of sexual activity. The recognition of the central role of HPV (...) Assessment, Development and Evaluation HPV Human papilloma virus ICER Incremental cost-effectiveness ratio ICO Istituto Catala' d'Oncologia (Spain) LY Life years 9vHPV Nine-valent HPV vaccine PeIN Penile intraepithelial neoplasia PICO Population Intervention Comparison Outcome POTS Postural orthostatic tachycardia syndrome QALY Quality-adjusted life years 6MPI Six-month persistent infection VaIN Vaginal intraepithelial neoplasia VLP Virus-like particle VIN Vulvar intraepithelial neoplasia Glossary Cost

2020 European Centre for Disease Prevention and Control - Technical Guidance

12. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

with HIV and 9-valent HPV vaccine introduction Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Technical guidance 30 Mar 2020 Cite: European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction, 2020. Stockholm: ECDC; 2020. This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas (...) not previously targeted by immunisation programmes: HIV-infected Data Evidence of the safety of the HPV vaccine in HIV-infected men and women Table - 30 Mar 2020 Efficacy, immunogenicity, safety and tolerability in other populations not previously targeted by immunisation programmes: HIV-infected men and women More on this topic Follow us: Footer Navigation © European Centre for Disease Prevention and Control (ECDC) 2020 Other sites: Search Search Search Search

2020 European Centre for Disease Prevention and Control - Technical Guidance

13. Primary Ovarian Insufficiency and Human Papilloma Virus Vaccines: A Review of the Current Evidence. (Abstract)

Primary Ovarian Insufficiency and Human Papilloma Virus Vaccines: A Review of the Current Evidence. Human papilloma virus is the primary causative agent for cervical cancer, and vaccination is the primary means of preventing anogenital cancers caused by human papilloma virus infection. Despite the availability of human papilloma virus vaccines for over a decade, coverage rates lag behind the other vaccines. Public concerns regarding safety of human papilloma virus vaccines have been identified (...) as an important barrier to vaccination, including concerns that the human papilloma virus vaccine causes primary ovarian insufficiency, driven in part by isolated reports of ovarian failure following the human papilloma virus vaccine. We summarize published peer-reviewed literature on human papilloma virus vaccines and primary ovarian insufficiency reviewing information contained in the case reports and series. Health care providers should address any patient concerns about primary ovarian insufficiency

2019 American Journal of Obstetrics and Gynecology

14. Knowledge towards human papilloma virus (HPV) infection and attitude towards its vaccine in the Kingdom of Bahrain: cross-sectional study. Full Text available with Trip Pro

Knowledge towards human papilloma virus (HPV) infection and attitude towards its vaccine in the Kingdom of Bahrain: cross-sectional study. To determine the level of awareness of human papilloma virus (HPV) infection and to assess attitudes towards receiving the vaccine among men and women in Bahrain.A cross-sectional study. An interview-based questionnaire was used to measure HPV knowledge and attitude towards HPV vaccine.Ten randomly selected primary health centres (PHCs) in the Kingdom (...) the community about the HPV infection.Despite the limited knowledge about HPV infection among the study's participants, there is a favourable attitude towards the HPV vaccine. These data can support the initiation of a nationwide HPV immunisation programme.© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

2019 BMJ open

15. Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. Full Text available with Trip Pro

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM).We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV (...) believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.

2019 BMC Public Health

16. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. Full Text available with Trip Pro

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. In recurrent human papilloma virus (HPV)-driven cancer, immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies produces tumor regression in only a minority of patients. Therapeutic HPV vaccines have produced strong immune responses to HPV-16, but vaccination alone has been ineffective for invasive cancer.To (...) determine whether the efficacy of nivolumab, an anti-PD-1 immune checkpoint antibody, is amplified through treatment with ISA 101, a synthetic long-peptide HPV-16 vaccine inducing HPV-specific T cells, in patients with incurable HPV-16-positive cancer.In this single-arm, single-center phase 2 clinical trial, 24 patients with incurable HPV-16-positive cancer were enrolled from December 23, 2015, to December 12, 2016. Duration of follow-up for censored patients was 12.2 months through August 31, 2017

2018 JAMA oncology Controlled trial quality: uncertain

17. Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. (Abstract)

Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. The ability of a quadrivalent human papilloma virus (HPV)-16/18/6/11 virus-like particles vaccine (Gardasil) to elicit HPV-specific cell-mediated immune responses was evaluated in antiretroviral therapy (ART)-treated HIV-infected young adults. Results showed that, after three doses of vaccine, central memory and effector memory CD4 (...) (+) and CD8(+) T lymphocytes, as well as HPV-specific interleukin (IL)2(+)/CD4(+), interferon-gamma (IFN-γ(+))/CD4(+), IFN-γ(+)/CD8(+) and tumour necrosis factor-alpha (TNF-α)(+)/CD8(+) T lymphocytes and Perforin and Granzyme B secreting CD8(+) T lymphocytes were significantly increased. Notably, results obtained in HIV-infected patients were comparable to those seen in HIV-uninfected age-matched healthy controls.

2015 AIDS

18. Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study

Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study | SCPHRP Publication Information Date of Publication 31/10/2012 Link

2012 Scottish Collaboration for Public Health Research & Policy

19. Randomized controlled trials to improve Human Papilloma Virus vaccine uptake in the United States: A systematic review with meta-analysis

Randomized controlled trials to improve Human Papilloma Virus vaccine uptake in the United States: A systematic review with meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

20. Human papilloma virus vaccination against cervical cancer in adult women: a systematic review and meta-analysis

Human papilloma virus vaccination against cervical cancer in adult women: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>